The cisplatin, epirubicin, 5‐fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma

Biliary tract adenocarcinoma (BTA) is an uncommon tumor with a poor prognosis and no standard, systemic chemotherapy. The combined cisplatin, epirubicin, 5‐fluorouracil, and gemcitabine (PEFG) regimen is an effective, upfront treatment for advanced pancreatic cancer. In this study, the authors assessed the activity and safety of this combination regimen in patients with advanced BTA.

[1]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[2]  J. Furuse,et al.  S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study , 2008, Cancer Chemotherapy and Pharmacology.

[3]  M. Reni,et al.  A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma , 2007 .

[4]  R. Schmid,et al.  Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials , 2007, British Journal of Cancer.

[5]  M. Reni,et al.  Dose-Intense PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) in Advanced Pancreatic Adenocarcinoma: A Dose-Finding Study , 2007, Cancer investigation.

[6]  V. Georgoulias,et al.  Oxaliplatin as First-Line Treatment in Inoperable Biliary Tract Carcinoma , 2006, Oncology.

[7]  P. Philip,et al.  Phase II study of erlotinib in patients with advanced biliary cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Reni,et al.  Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma , 2006, Cancer Chemotherapy and Pharmacology.

[9]  S. Park,et al.  Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma , 2006, Cancer.

[10]  G. Abou-Alfa,et al.  A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers , 2005, American journal of clinical oncology.

[11]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[12]  T. Hickish,et al.  Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF , 2005, British Journal of Cancer.

[13]  D. Smith,et al.  Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer , 2005, British Journal of Cancer.

[14]  G. Pond,et al.  Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Thongprasert,et al.  Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  E. Van Cutsem,et al.  A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. , 2005, European journal of cancer.

[17]  C. Tournigand,et al.  Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Manal M. Hassan,et al.  Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma , 2004, Cancer.

[19]  G. Pond,et al.  Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  W. Scheithauer,et al.  Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Myung Ah Lee,et al.  Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[22]  H. Ueno,et al.  Phase II Study of Cisplatin, Epirubicin, and Continuous-Infusion 5-Fluorouracil for Advanced Biliary Tract Cancer , 2003, Oncology.

[23]  R. Goldberg,et al.  CPT-11 for bile-duct and gallbladder carcinoma , 2002, International journal of gastrointestinal cancer.

[24]  H. Hass,et al.  Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial , 2002, British Journal of Cancer.

[25]  M. Ducreux,et al.  Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Manal M. Hassan,et al.  Phase II Trial of Cisplatin, Interferon α-2b, Doxorubicin, and 5-Fluorouracil for Biliary Tract Cancer , 2001 .

[27]  G. Colucci,et al.  Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Reni,et al.  Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Lawrence,et al.  Interaction between gemcitabine and mitomycin-C in vitro , 2000, Cancer Chemotherapy and Pharmacology.

[30]  G. Gores,et al.  Biliary tract cancers. , 1999, The New England journal of medicine.

[31]  R. Jenkins,et al.  A phase II trial of 5‐fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma , 1998, Cancer.

[32]  T. Linné,et al.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  T. Hickish,et al.  Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. , 1995, European journal of cancer.

[34]  T. Takada,et al.  Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. , 1994, Oncology.

[35]  J. Furuse,et al.  A phase II study of cisplatin in patients with biliary tract carcinoma. , 1994, Oncology.

[36]  S. Pyrhönen,et al.  Epirubicin‐Sequential Methotrexate‐5‐Fluorouracil‐Leucovorin Treatment in Advanced Cancer of the Extrahepatic Biliary System: A Phase II Study , 1994, American journal of clinical oncology.

[37]  R. Audisio,et al.  Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  P. Schein,et al.  5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Moertel,et al.  Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer , 1984, Cancer.

[40]  G. Ramírez,et al.  Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy , 1974, Cancer.

[41]  S. Alberts,et al.  Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma , 2005, Cancer.

[42]  J. Yook,et al.  Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  L. Schouten,et al.  Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands. , 1993, Cancer investigation.

[44]  Susan Rea Welch,et al.  Comprehensive criteria for assessing therapy-induced toxicity. , 1990, Cancer investigation.